Buoyed by US revenues, higher growth trajectory awaits Ajanta Pharma

Topics Ajanta Pharma

A strong uptick in US revenues, traction in the Africa business, and consistent performance in the domestic market have led to brokerage upgrades for Ajanta Pharma. The stock is up 27 per cent since the start of February. Analysts at SBICAP Research have upgraded the stock to a “buy” on improved growth visibility across businesses, sustained outperformance in India business, and structural margin expansion from leverage. They expect revenue growth to be in high teens in the FY19-22 period, driven by 25 per cent growth in the US and low-to-mid teens growth in its branded busin.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.